Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

 

Search in our Online Store

Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles Print E-mail
02 Jul 2008

Top-line Data Expected in August

EXTON, PA, USA | July 2, 2008 | Isolagen(TM), Inc. (Amex: ILE) announced today the completion of the pivotal efficacy portion of its Phase III clinical studies (IT-R-005/006) investigating the Isolagen Therapy(TM) for the treatment of nasolabial folds, or wrinkles. The last person in each study has completed the primary efficacy follow-up visit, and collation of this data has begun. The Company anticipates that top-line efficacy and safety data analyses from the studies will be reported in August 2008.

The completion of the pivotal efficacy portion of our Phase III clinical studies is a major milestone for Isolagen, said Declan Daly, Chief Executive Officer of Isolagen. I commend the Isolagen team and our investigators for their efforts and look forward to announcing the data once it is un-blinded later this summer.

About the Isolagen Process(TM) and Isolagen Therapy(TM)

The Isolagen Process(TM) is an innovative cellular processing system which creates a natural, living cell therapy. By multiplying a patient's own collagen-producing cells or fibroblasts into tens of millions of new cells, a personalized treatment is created which is then returned to the patient's skin. This treatment, known as the Isolagen Therapy, is designed to improve skin damage caused by the normal effects of aging, sun damage, acne and burns.

About Isolagen, Inc.

Isolagen(TM), Inc. (Amex: ILE) is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company's technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera(R) Laboratories, Inc. For additional information, please visit http://www.isolagen.com.

SOURCE Isolagen, Inc.





Digg!Reddit!Del.icio.us!Google!Live!Facebook!Slashdot!Netscape!Technorati!StumbleUpon!Spurl!Wists!Simpy!Newsvine!Blinklist!Furl!Fark!Blogmarks!Yahoo!Smarking!Netvouz!Shadows!RawSugar!Ma.gnolia!PlugIM!Squidoo!BlogMemes!FeedMeLinks!BlinkBits!Tailrank!linkaGoGo!Free social bookmarking plugins and extensions for Joomla! websites! title=
 

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Emerging Diabetes Drugs

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics